Literature DB >> 25977264

Effect of Preexisting Serum and Mucosal Antibody on Experimental Respiratory Syncytial Virus (RSV) Challenge and Infection of Adults.

Bindiya Bagga1, Jeffrey E Cehelsky2, Akshay Vaishnaw2, Tom Wilkinson3, Rachel Meyers2, Lisa M Harrison4, Philippa L Roddam1, Edward E Walsh5, John P DeVincenzo6.   

Abstract

We studied preexisting respiratory syncytial virus (RSV)-specific serum and nasal antibodies and their correlation with infectivity, viral dynamics, and disease severity in a human experimental infection model. Higher preinoculation serum neutralizing antibody titers and nasal immunoglobulin (Ig) A predicted lower infectivity and lower measures of viral replication. However, once individuals were infected, no significant protective effect of preexisting antibodies was seen. Lack of correlation between serum and mucosal antibodies was observed, implying that they are independent co-correlates of protection against RSV infection. We suggest that protection from RSV infection is a function of a complex interplay between mucosal and serum humoral immune responses.
© The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  correlates of protection; mucosal antibody responses; respiratory syncytial virus; serum antibody responses; vaccines

Mesh：

Substances：

Year:  2015        PMID： 25977264     DOI： 10.1093/infdis/jiv281

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  42 in total

Review 1.  Vaccine Design Informed by Virus-Induced Immunity.

Authors:  Rhiannon R Penkert; Jane S Hankins; Neal S Young; Julia L Hurwitz
Journal:  Viral Immunol       Date:  2020-05-05       Impact factor: 2.257

2.  An Equine Herpesvirus Type 1 (EHV-1) Ab4 Open Reading Frame 2 Deletion Mutant Provides Immunity and Protection from EHV-1 Infection and Disease.

Authors:  Christiane L Schnabel; Susanna Babasyan; Alicia Rollins; Heather Freer; Christine L Wimer; Gillian A Perkins; Fahad Raza; Nikolaus Osterrieder; Bettina Wagner
Journal:  J Virol       Date:  2019-10-29       Impact factor: 5.103

3.  Antibody and B cell responses to an investigational adjuvanted RSV vaccine for older adults.

Authors:  Adriana Weinberg; Stacie L Lambert; Jennifer Canniff; Li Yu; Nancy Lang; Mark T Esser; Judith Falloon; Myron J Levin
Journal:  Hum Vaccin Immunother       Date:  2019-06-03       Impact factor: 3.452

4.  Vaccination strategies against respiratory syncytial virus.

Authors:  Dan Yamin; Forrest K Jones; John P DeVincenzo; Shai Gertler; Oren Kobiler; Jeffrey P Townsend; Alison P Galvani
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-31       Impact factor: 11.205

5.  T-Cell Responses in Adults During Natural Respiratory Syncytial Virus Infection.

Authors:  D Roumanes; A R Falsey; S Quataert; S Secor-Socha; F E-H Lee; H Yang; S Bandyopadhyay; J Holden-Wiltse; D J Topham; E E Walsh
Journal:  J Infect Dis       Date:  2018-07-02       Impact factor: 5.226

Review 6.  Aberrant T cell immunity triggered by human Respiratory Syncytial Virus and human Metapneumovirus infection.

Authors:  Andrea E González; Margarita K Lay; Evelyn L Jara; Janyra A Espinoza; Roberto S Gómez; Jorge Soto; Claudia A Rivera; Katia Abarca; Susan M Bueno; Claudia A Riedel; Alexis M Kalergis
Journal:  Virulence       Date:  2016-12-02       Impact factor: 5.882

7.  Prolonged viral replication and longitudinal viral dynamic differences among respiratory syncytial virus infected infants.

Authors:  Monica E Brint; Joshua M Hughes; Aditya Shah; Chelsea R Miller; Lisa G Harrison; Elizabeth A Meals; Jacqueline Blanch; Charlotte R Thompson; Stephania A Cormier; John P DeVincenzo
Journal:  Pediatr Res       Date:  2017-08-09       Impact factor: 3.756

Review 8.  Integrative Physiology of Pneumonia.

Authors:  Lee J Quinton; Allan J Walkey; Joseph P Mizgerd
Journal:  Physiol Rev       Date:  2018-07-01       Impact factor: 37.312

Review 9.  The Human Immune Response to Respiratory Syncytial Virus Infection.

Authors:  Clark D Russell; Stefan A Unger; Marc Walton; Jürgen Schwarze
Journal:  Clin Microbiol Rev       Date:  2017-04       Impact factor: 26.132

10.  Prefusion F-Based Polyanhydride Nanovaccine Induces Both Humoral and Cell-Mediated Immunity Resulting in Long-Lasting Protection against Respiratory Syncytial Virus.

Authors:  Laura M Stephens; Kathleen A Ross; Kody A Waldstein; Kevin L Legge; Jason S McLellan; Balaji Narasimhan; Steven M Varga
Journal:  J Immunol       Date:  2021-04-07       Impact factor: 5.422
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.